Ratings MaaT Pharma

Equities

MAAT

FR0012634822

Market Closed - Euronext Paris Other stock markets 09:48:36 2024-06-05 am EDT			5-day change	1st Jan Change
7.9 ^EUR	0.00%		-1.25%	+13.18%

May. 08	Mickey Mouse on Wall Street
Apr. 15	MaaT Pharma: positive data in graft-versus-host disease	CF

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MAAT PHARMA	+13.18%	119M	-
VERTEX PHARMACEUTICALS INCORPORATED	+18.56%	123B	B+
REGENERON PHARMACEUTICALS, INC.	+15.32%	107B	B+
BIONTECH SE	-3.87%	24.01B	B+
ARGENX SE	+2.18%	22.59B	B
GENMAB A/S	-10.09%	18.16B	A-
WUXI APPTEC CO., LTD.	-41.04%	16.84B	A-
BEIGENE, LTD.	-13.06%	16.23B	B
NEUROCRINE BIOSCIENCES, INC.	+3.08%	13.43B	C+
SAREPTA THERAPEUTICS, INC.	+25.04%	11.32B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes